Clinical trialNCT02509156CompletedPhase 1Interventional

Stem Cell Injection in Cancer Survivors

SponsorThe University of Texas Health Science Center, HoustonEnrollment46Cardiomyopathy Due to Anthracyclines

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer survivors with left ventricular (LV) dysfunction secondary to anthracycline-induced cardiomyopathy (AIC). The secondary purpose of this study is to obtain preliminary evidence for therapeutic efficacy of allo-MSCs delivered by transendocardial injection to cancer survivors with LV dysfunction secondary to AIC.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Robert Simari, MD
CCTRN Steering Committee Chair
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Stanford University School of Medicine
Stanford, California, United States
University of Florida-Department of Medicine
Gainesville, Florida, United States
University of Miami-Interdiciplinary Stem Cell Institute
Miami, Florida, United States
Indiana Center for Vascular Biology and Medicine
Indianapolis, Indiana, United States
University of Louisville
Louisville, Kentucky, United States
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, United States
Texas Heart Institute
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Allo-MSCsPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2016
Primary completion: 30 Nov 2019
Completion: 20 Apr 2020
Last update posted: 5 Nov 2020
Registered enrollment: 46
Registry id: NCT02509156

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.